Data as of Oct 22
| +0.20 / +2.62%|
The 4 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 9.50. The median estimate represents a +65.82% increase from the last price of 7.84.
The current consensus among 4 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.